• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The "popcorn" sign: the first early ultrasound sign of serous intra-parenchymal ovarian cancer in BRCA mutation carriers.

作者信息

Grandi Giovanni, Sgandurra Alice, Cortesi Laura, Toss Angela, Dominici Massimo, Grisendi Valentina, Pedrini Valeria, Botticelli Laura, La Marca Antonio

机构信息

Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero Universitaria, Via del Pozzo 71, 41124, Modena, Italy.

Department of Obstetrics, Gynecology and Pediatrics, Obstetrics and Gynecology Unit, Azienda Ospedaliero-Universitaria, University of Modena and Reggio Emilia, Via del Pozzo 71, 41124, Modena, Italy.

出版信息

Arch Gynecol Obstet. 2025 May;311(5):1461-1465. doi: 10.1007/s00404-025-08010-w.

DOI:10.1007/s00404-025-08010-w
PMID:40105936
Abstract
摘要

相似文献

1
The "popcorn" sign: the first early ultrasound sign of serous intra-parenchymal ovarian cancer in BRCA mutation carriers.“爆米花”征：BRCA 突变携带者浆液性卵巢实质内癌的首个早期超声征象。
Arch Gynecol Obstet. 2025 May;311(5):1461-1465. doi: 10.1007/s00404-025-08010-w.
2
Evaluation of Microscopic Changes in Fallopian Tubes of BRCA Mutation Carriers by Morphometric Analysis of Histologic Slides: A Preliminary Pilot Study.通过组织学切片的形态计量分析评估BRCA突变携带者输卵管的微观变化：一项初步试点研究。
Int J Gynecol Pathol. 2018 Sep;37(5):460-467. doi: 10.1097/PGP.0000000000000440.
3
Association Between Germline Gene Variants and Clinicopathological Features of Ovarian Cancer.生殖系基因变异与卵巢癌临床病理特征之间的关联
Int J Gen Med. 2024 Jan 11;17:75-84. doi: 10.2147/IJGM.S445660. eCollection 2024.
4
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.BRCA2 相关浆液性卵巢癌的生存改善优于 BRCA 阴性和 BRCA1 相关浆液性卵巢癌。
Cancer. 2012 Aug 1;118(15):3703-9. doi: 10.1002/cncr.26655. Epub 2011 Dec 2.
5
BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.BRCA 突变检测用于高分级浆液性卵巢癌女性的一级亲属。
Gynecol Oncol. 2019 Mar;152(3):459-464. doi: 10.1016/j.ygyno.2018.10.014.
6
Chemotherapy Toxicity in Mutation Carriers Undergoing First-Line Platinum-Based Chemotherapy.一线基于铂类化疗的突变携带者的化疗毒性。
Oncologist. 2019 Dec;24(12):e1471-e1475. doi: 10.1634/theoncologist.2019-0272. Epub 2019 Jul 25.
7
Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma.在盆腔浆液性癌高危女性的卵巢和输卵管微环境中存在生物标志物和内输卵管上皮化生。
Am J Cancer Res. 2014 Jan 15;4(1):61-72. eCollection 2014.
8
Computerized morphometry analysis of epithelial fimbriae nuclear symmetry in BRCA carriers may identify patients at risk for developing ovarian cancer.BRCA 携带者上皮纤毛核对称性的计算机形态计量分析可能有助于识别发生卵巢癌的风险患者。
Microsc Res Tech. 2022 Mar;85(3):892-899. doi: 10.1002/jemt.23958. Epub 2021 Oct 9.
9
Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.BRCA1/2突变携带者输卵管上皮中潜在的浆液性癌前体。
Mod Pathol. 2009 Sep;22(9):1133-8. doi: 10.1038/modpathol.2009.89. Epub 2009 Jun 19.
10
Pathologic Findings at Risk Reducing Surgery in and Non- Mutation Carriers: A Single-Center Experience.携带和未携带突变者进行降低风险手术时的病理结果：单中心经验
Diagnostics (Basel). 2022 Dec 6;12(12):3054. doi: 10.3390/diagnostics12123054.

本文引用的文献

1
It's Better to Operate with Eyes Open - Applications and Perspectives of Intraoperative Ultrasound (IOUS) in Gynecological Procedures.
Ultraschall Med. 2024 Dec;45(6):557-563. doi: 10.1055/a-2408-0979. Epub 2024 Dec 11.
2
Reply to the Letter to the Editor 'There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes (in regard to "ESMO Clinical Practice Guideline on risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes")' by W. Tjalma.对W. Tjalma所著《致编辑的信：遗传性乳腺癌-卵巢癌综合征中卵巢癌筛查无立足之地（关于“ESMO遗传性乳腺癌-卵巢癌综合征癌症风险降低与筛查临床实践指南”）》的回复
Ann Oncol. 2024 Jan;35(1):139-140. doi: 10.1016/j.annonc.2023.10.119. Epub 2023 Oct 28.
3
The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance.BRCA 基因突变携带者遵循 6 个月随访方案时卵巢癌的挑战性筛查：6 年监测结果。
Menopause. 2021 Nov 1;29(1):63-72. doi: 10.1097/GME.0000000000001883.
4
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update.卵巢、输卵管及腹膜癌：2021年更新
Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(Suppl 1):61-85. doi: 10.1002/ijgo.13878.
5
Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.英国卵巢癌筛查协作试验（UKCTOCS）长期随访后的卵巢癌人群筛查和死亡率：一项随机对照试验。
Lancet. 2021 Jun 5;397(10290):2182-2193. doi: 10.1016/S0140-6736(21)00731-5. Epub 2021 May 12.
6
Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study.体重指数（BMI）的增加与子宫内膜癌而不是卵巢癌中的子宫内膜样和浆液性组织类型均相关：病例对照研究。
Gynecol Oncol. 2019 Jul;154(1):163-168. doi: 10.1016/j.ygyno.2019.04.684. Epub 2019 May 16.
7
Hereditary ovarian cancers: state of the art.遗传性卵巢癌：最新进展。
Minerva Med. 2019 Aug;110(4):301-319. doi: 10.23736/S0026-4806.19.06091-9. Epub 2019 May 6.
8
Ovarian Cancer: An Integrated Review.卵巢癌：综合述评。
Semin Oncol Nurs. 2019 Apr;35(2):151-156. doi: 10.1016/j.soncn.2019.02.001. Epub 2019 Mar 11.
9
Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study.经阴道超声联合CA-125检测及预防性输卵管卵巢切除术在不同卵巢癌风险水平女性中的评估：摩德纳研究组队列研究
Oncology. 2017;93(6):377-386. doi: 10.1159/000479155. Epub 2017 Aug 26.
10
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.BRCA1 和 BRCA2 基因突变携带者的乳腺癌、卵巢癌和对侧乳腺癌风险。
JAMA. 2017 Jun 20;317(23):2402-2416. doi: 10.1001/jama.2017.7112.